MedTrace Logo

Phase I Trial of Tanibirumab in Advanced or Metastatic Cancer

NCT01660360 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2014-01-29

No results posted yet for this study

Summary

The primary objective of this study is to assess the safety, tolerability, and maximum tolerated dose (MTD) of Tanibirumab in patients with advanced or metastatic cancer who are refractory or for whom there are no standard therapeutic option.

* To evaluate the pharmacokinetics of Tanibirumab in such patients
* To determine a recommended phase II dose (RP2D) of Tanibirumab based on above assessments

Conditions

Interventions

BIOLOGICAL

Tanibirumab

Sponsors & Collaborators

  • PharmAbcine

    lead INDUSTRY

Principal Investigators

  • Young Seok Park, MD, PhD · Samsung Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01660360 on ClinicalTrials.gov